Active Biotech Management
Management criteria checks 3/4
Active Biotech's CEO is Helen Tuvesson, appointed in Jul 2017, has a tenure of 6.75 years. total yearly compensation is SEK4.05M, comprised of 56% salary and 44% bonuses, including company stock and options. directly owns 0.071% of the company’s shares, worth SEK136.08K. The average tenure of the management team and the board of directors is 6.8 years and 4.9 years respectively.
Key information
Helen Tuvesson
Chief executive officer
kr4.0m
Total compensation
| CEO salary percentage | 56.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.07% |
| Management average tenure | 6.8yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?
Feb 19
Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely
Jul 27Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely
May 07Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Nov 09We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely
May 03We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate
Jan 18
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | kr4m | kr2m | -kr46m |
| Sep 30 2023 | n/a | n/a | -kr48m |
| Jun 30 2023 | n/a | n/a | -kr51m |
| Mar 31 2023 | n/a | n/a | -kr54m |
| Dec 31 2022 | kr4m | kr2m | -kr58m |
| Sep 30 2022 | n/a | n/a | -kr60m |
| Jun 30 2022 | n/a | n/a | -kr57m |
| Mar 31 2022 | n/a | n/a | -kr56m |
| Dec 31 2021 | kr4m | kr2m | -kr50m |
| Sep 30 2021 | n/a | n/a | -kr38m |
| Jun 30 2021 | n/a | n/a | -kr35m |
| Mar 31 2021 | n/a | n/a | -kr32m |
| Dec 31 2020 | kr3m | kr2m | -kr32m |
| Sep 30 2020 | n/a | n/a | -kr39m |
| Jun 30 2020 | n/a | n/a | -kr40m |
| Mar 31 2020 | n/a | n/a | -kr36m |
| Dec 31 2019 | kr3m | kr2m | -kr34m |
| Sep 30 2019 | n/a | n/a | -kr32m |
| Jun 30 2019 | n/a | n/a | -kr31m |
| Mar 31 2019 | n/a | n/a | -kr35m |
| Dec 31 2018 | kr3m | kr1m | -kr37m |
| Sep 30 2018 | n/a | n/a | -kr88m |
| Jun 30 2018 | n/a | n/a | -kr88m |
| Mar 31 2018 | n/a | n/a | -kr103m |
| Dec 31 2017 | kr2m | kr1m | -kr109m |
Compensation vs Market: Helen's total compensation ($USD371.54K) is above average for companies of similar size in the Swedish market ($USD238.31K).
Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.
CEO
Helen Tuvesson (61 yo)
6.8yrs
Tenure
kr4,045,000
Compensation
Ms. Helen Tuvesson, Ph.D. is President of Active Biotech AB and its Chief Executive Officer since 2017. She serves as Independent Director at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 6.8yrs | kr4.05m | 0.071% SEK 136.1k | |
| Chief Financial Officer | 24.3yrs | no data | 0.051% SEK 97.9k | |
| Chief Medical Officer | 2.3yrs | no data | 0.024% SEK 47.0k |
6.8yrs
Average Tenure
61yo
Average Age
Experienced Management: ACTI's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 12.9yrs | kr206.00k | no data | |
| Independent Director | 4.9yrs | kr202.00k | 0.0058% SEK 11.2k | |
| Independent Chairman of the Board | 4.9yrs | kr524.00k | 0.12% SEK 224.3k | |
| Independent Director | 3.9yrs | kr203.00k | 0.011% SEK 21.3k | |
| Independent Director | 3.9yrs | kr207.00k | 0.037% SEK 71.1k |
4.9yrs
Average Tenure
63yo
Average Age
Experienced Board: ACTI's board of directors are considered experienced (4.9 years average tenure).